2 assets in Hyper-IgM Syndrome Type 3

Therapeutic assets addressing Hyper-IgM Syndrome Type 3, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ibrutinib Hyper-IgM Syndrome Type 3	Chinese Academy of Medical Sciences	P2	CCC (53)
Rituximab Hyper-IgM Syndrome Type 3	Chinese Academy of Medical Sciences	P2	CCC (53)